-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

Benzinga·09/10/2026 15:09:19
Listen to the news
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.